HCA Healthcare (HCA)
(Delayed Data from NYSE)
$415.54 USD
+9.06 (2.23%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $415.66 +0.12 (0.03%) 4:32 PM ET
2-Buy of 5 2
A Value B Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$415.54 USD
+9.06 (2.23%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $415.66 +0.12 (0.03%) 4:32 PM ET
2-Buy of 5 2
A Value B Growth D Momentum A VGM
Zacks News
Acadia Healthcare, Covenant Health to Offer Mental Healthcare
by Zacks Equity Research
Acadia Healthcare (ACHC) and Covenant Health to unveil East Tennessee Behavioral Health to cater to the mental care services of communities in and around Knoxville.
Why Should You Retain HCA Healthcare in Your Portfolio?
by Zacks Equity Research
Gaining traction from strategic moves and a solid uptake of telehealth medicines, HCA Healthcare (HCA) holds prospects of reaping benefits for investors.
HCA (HCA) Up 3.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
HCA (HCA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tenet Healthcare Up 39% in a Year: Further Upside Left?
by Zacks Equity Research
Tenet Healthcare's (THC) strategic measures and cost-controlling efforts are expected to support its margins, which in turn, might perk up its share price.
Stocks Continue to Climb, Even Without a New Stimulus Deal
by David Borun
Both the House and Senate leave Washington without settling on new Covid-19 aid package, but US equities grind higher anyway.
Community Health Up 118.9% in a Year: Further Upside Left?
by Zacks Equity Research
Community Health's (CYH) strategic measures are likely to fetch revenues, which in turn, may bump up its share price.
Ensign Group's (ENSG) Q2 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Ensign Group's (ENSG) Q2 earnings results reflect better revenues from its Transitional and Skilled Services segment.
Humana's (HUM) Q2 Earnings Surpass Estimates, Improve Y/Y
by Zacks Equity Research
Humana's (HUM) Q2 earnings reflect better revenues and solid contributions from its Retail and Healthcare Services segments.
Tenet Healthcare (THC) Q2 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Tenet Healthcare's (THC) Q2 earnings gain from operational performance, partly offset by lower revenues.
Select Medical's (SEM) Q2 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Select Medical's (SEM) second-quarter earnings performance benefits from lower expenses.
MEDNAX's (MD) Q2 Earnings Surpass Estimates, Decline Y/Y
by Zacks Equity Research
MEDNAX's (MD) Q2 results reflect lower expenses, offset by soft revenues.
Molina Healthcare (MOH) Q2 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Molina Healthcare's (MOH) Q2 results reflect higher revenues and membership growth.
Teladoc (TDOC) Q2 Earnings Lag Estimates, Revenues Up Y/Y
by Zacks Equity Research
Teladoc's (TDOC) second-quarter results reflect higher revenues and solid rise in patient visits, partially offset by increased expenses.
Anthem (ANTM) Q2 Earnings Surpass Estimates, Improve Y/Y
by Zacks Equity Research
Anthem's (ANTM) Q2 results reflect higher premium revenues and a solid contribution from Government business.
Community Health (CYH) Q2 Earnings Beat, Revenues Down Y/Y
by Zacks Equity Research
Community Health's (CYH) second-quarter results reflect lower costs, partially offset by softer revenues owing to decline in admissions.
5 Healthcare Stocks to Beat on Q2 Earnings Despite Coronavirus
by Zacks Equity Research
Companies across the healthcare sector experience a mixed impact from coronavirus. While some gain traction from a surge in virtual care, the rest suffers demand woes and supply-chain glitches.
Universal Health (UHS) Q2 Earnings Beat, Revenues Down Y/Y
by Zacks Equity Research
Universal Health's (UHS) second-quarter earnings reflect lower expenses, partially offset by reduced patient volumes.
Company News for Jul 23, 2020
by Zacks Equity Research
Companies In The News Are: HCA, TMO, ABB, APH.
HCA Healthcare's (HCA) Q2 Earnings Beat Estimates, Fall Y/Y
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter results reflect lower expenses, partly offset by a decline in admissions.
HCA Holdings (HCA) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of 259.57% and 17.72%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Quiet Week Could be the Calm Before the Storm
by David Borun
A busy week of earnings reports and Congressional stimulus talks has t
What's in Store for HCA Healthcare's (HCA) Q2 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter results are likely to reflect dented revenues due to the pandemic woes.
Earnings Preview: HCA Holdings (HCA) Q2 Earnings Expected to Decline
by Zacks Equity Research
HCA (HCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Steer Clear of MEDNAX (MD) at Present
by Zacks Equity Research
Pressure from the COVID-19 impact on global economy and lack of solvency make MEDNAX (MD) an unattractive bet.
Tenet Healthcare Plunges 55.7% YTD: Will the Stock Rebound?
by Zacks Equity Research
Even though Tenet Healthcare (THC) endures the COVID-19 impact on global economy, it holds prospects to revive its fortunes with the help of its endeavors and strong fundamentals.